Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]
In development [GID-TA10597] Expected publication date: 27 October 2021
Search results
725 results
-
-
Third molars (impacted) - prophylactic removal [ID898]
In development [GID-TAG525] Expected publication date: TBC
-
Pembrolizumab in combination with chemotherapy for neoadjuvant treatment of triple negative breast cancer [ID1500]
In development [GID-TA10399] Expected publication date: TBC
-
Selumetinib for treating differentiated thyroid cancer ID1079
In development [GID-TA10207] Expected publication date: TBC
-
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]
In development [GID-TA10249] Expected publication date: TBC
-
NY-ESO-1 T-cells for treating synovial sarcoma ID1286
In development [GID-TA10205] Expected publication date: TBC
-
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]
In development [GID-TA10251] Expected publication date: TBC
-
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297
In development [GID-TA10311] Expected publication date: TBC
-
Ovarian, fallopian tube and peritoneal cancer - rucaparib [ID1184]
In development [GID-TA10168] Expected publication date: TBC
-
Enzalutamide for the treatment of hormone refractory prostate cancer TA316
In development [GID-TA10267] Expected publication date: TBC
-
ATA129 for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus ID1203
In development [GID-TA10204] Expected publication date: TBC
-
Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340
In development [GID-TA10313] Expected publication date: TBC
-
Fenfluramine hydrochloride for treating Lennox-Gastaut seizures in people aged 2 and over [ID1651]
In development [GID-TA10653] Expected publication date: TBC
-
Lenvatinib with everolimus or pembrolizumab for untreated advanced renal cell carcinoma [ID3760]
In development [GID-TA10629] Expected publication date: TBC
-
TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices [ID1440]
In development [GID-TA10370] Expected publication date: TBC
-
Baloxavir marboxil for treating influenza [ID1537]
In development [GID-TA10559] Expected publication date: TBC
-
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]
Technology appraisal [TA582] Published date: 24 May 2019
-
Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]
In development [GID-TA10664] Expected publication date: TBC
-
Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]
In development [GID-TA10711] Expected publication date: 15 September 2021
-
Crizanlizumab for preventing sickle cell crises in sickle cell disease [ID1406]
In development [GID-TA10470] Expected publication date: TBC
-
Belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus (Review of TA397) [ID1591]
In development [GID-TA10626] Expected publication date: 21 July 2021
-
Sodium thiosulfate for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy [ID1001]
In development [GID-TA10611] Expected publication date: TBC
-
Relugolix with oestradiol and norethindrone acetate for heavy menstrual bleeding associated with uterine fibroids [ID3842]
In development [GID-TA10734] Expected publication date: 09 March 2022
-
Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies [ID3828]
In development [GID-TA10708] Expected publication date: 22 December 2021
-
Nivolumab for adjuvant treatment of oesophageal or gastro-oesophageal junction cancer [ID1676]
In development [GID-TA10743] Expected publication date: 17 November 2021
-
Nintedanib for treating progressive fibrosing interstitial lung disease [ID1599]
In development [GID-TA10520] Expected publication date: 15 September 2021
-
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma [ID1609]
In development [GID-TA10498] Expected publication date: 13 October 2021
-
Cenobamate for focal onset seizures in epilepsy [ID1553]
In development [GID-TA10661] Expected publication date: 13 October 2021
-
Berotralstat for preventing acute attacks of hereditary angioedema [ID1624]
In development [GID-TA10650] Expected publication date: 25 August 2021
-
Risdiplam for treating spinal muscular atrophy in children and adults [ID1631]
In development [GID-TA10612] Expected publication date: 21 July 2021
-
Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (CDF Review TA490) [ID1585]
In development [GID-TA10538] Expected publication date: TBC
-
Zanubrutinib for treating Waldenström's macroglobulinaemia [ID1427]
In development [GID-TA10705] Expected publication date: 17 November 2021
-
Nivolumab for treating resected high-risk invasive urothelial cancer [ID2694]
In development [GID-TA10742] Expected publication date: 05 January 2022
-
Cemiplimab for untreated PD-L1-postive advanced or metastatic non-small-cell lung cancer [ID3839]
In development [GID-TA10725] Expected publication date: TBC
-
Pembrolizumab in combination for untreated, locally recurrent inoperable or metastatic, triple negative breast cancer [ID1546]
In development [GID-TA10417] Expected publication date: 15 September 2021
-
Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID968]
In development [GID-TA10334] Expected publication date: TBC
-
Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]
In development [GID-TA10606] Expected publication date: 08 June 2022
-
Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations [ID3761]
In development [GID-TA10630] Expected publication date: 23 March 2022
-
Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma in people who have received at least 3 prior therapies [ID1442]
In development [GID-TA10672] Expected publication date: TBC
-
Daratumumab in combination for untreated multiple myeloma when stem cell transplant is suitable [ID1510]
In development [GID-TA10449] Expected publication date: TBC
-
Pembrolizumab with platinum-based chemotherapy for untreated advanced oesophageal cancer [ID3741]
In development [GID-TA10613] Expected publication date: 13 October 2021
-
Secukinumab for treating plaque psoriasis in children and young people [ID1669]
In development [GID-TA10554] Expected publication date: 20 October 2021
-
Tebentafusp for treating metastatic or unresectable HLA-A*02:01 positive uveal melanoma [ID1441]
In development [GID-TA10428] Expected publication date: 20 July 2022
-
Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy [ID1410]
In development [GID-TA10391] Expected publication date: TBC
-
Esketamine for treating major depressive disorder in adults at imminent risk for suicide ID1604
In development [GID-TA10518] Expected publication date: TBC
-
Venetoclax with a hypomethylating agent or low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable [ID1564]
In development [GID-TA10478] Expected publication date: 22 September 2021
-
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma [ID3795]
In development [GID-TA10645] Expected publication date: 10 August 2022
-
Ticagrelor for preventing stroke after previous ischaemic stroke or high-risk transient ischaemic attack [ID2689]
In development [GID-TA10663] Expected publication date: 01 June 2022
-
Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in adults with elevated triglycerides [ID3831]
In development [GID-TA10736] Expected publication date: 05 January 2022
-
Nivolumab with ipilimumab for untreated recurrent or metastatic squamous cell cancer of the head and neck cancer ID1429
In development [GID-TA10512] Expected publication date: 22 June 2022